Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra(University of Maryland, Baltimore), Robert I. Haddad(Georgetown University), Shilpa Gupta(Cleveland Clinic), Barbara Burtness(Yale University), Chia‐Chi Lin(National Taiwan University Hospital), Joseph P. Eder(Yale Cancer Center), Ravit Geva(Tel Aviv Sourasky Medical Center), Laura Q.M. Chow(The University of Texas at Austin), Hyunseok Kang(Johns Hopkins University), Kei Muro(Aichi Cancer Center), Deepti Aurora-Garg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bhumsuk Keam(Seoul National University Hospital), Kumudu Pathiraja(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hyun Cheol Chung(Yonsei University), Jared Weiss(Georgetown University), Archana Ray(Merck & Co., Inc., Rahway, NJ, USA (United States)), Iris Gluck(Sheba Medical Center), Tanguy Y. Seiwert(Georgetown University), Jonathan D. Cheng(Princeton University), Makoto Tahara(National Cancer Center Hospital East)
Cited by 457
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k